DE69430664T2 - Indolin-2-on-derivate - Google Patents

Indolin-2-on-derivate

Info

Publication number
DE69430664T2
DE69430664T2 DE69430664T DE69430664T DE69430664T2 DE 69430664 T2 DE69430664 T2 DE 69430664T2 DE 69430664 T DE69430664 T DE 69430664T DE 69430664 T DE69430664 T DE 69430664T DE 69430664 T2 DE69430664 T2 DE 69430664T2
Authority
DE
Germany
Prior art keywords
lower alkyl
heterocycle
aryl
acyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430664T
Other languages
German (de)
English (en)
Other versions
DE69430664D1 (de
Inventor
Toru Esaki
Takashi Emura
Eiichi Hoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE69430664D1 publication Critical patent/DE69430664D1/de
Application granted granted Critical
Publication of DE69430664T2 publication Critical patent/DE69430664T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE69430664T 1993-02-17 1994-02-17 Indolin-2-on-derivate Expired - Fee Related DE69430664T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6729793 1993-02-17
JP16726293 1993-05-31
PCT/JP1994/000235 WO1994019322A1 (en) 1993-02-17 1994-02-17 Indolin-2-one derivative

Publications (2)

Publication Number Publication Date
DE69430664D1 DE69430664D1 (de) 2002-06-27
DE69430664T2 true DE69430664T2 (de) 2003-01-30

Family

ID=26408486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430664T Expired - Fee Related DE69430664T2 (de) 1993-02-17 1994-02-17 Indolin-2-on-derivate

Country Status (19)

Country Link
US (5) US5952511A (US06559137-20030506-C00039.png)
EP (1) EP0685463B1 (US06559137-20030506-C00039.png)
JP (1) JP3419539B2 (US06559137-20030506-C00039.png)
KR (1) KR100226310B1 (US06559137-20030506-C00039.png)
CN (1) CN1046268C (US06559137-20030506-C00039.png)
AT (1) ATE217864T1 (US06559137-20030506-C00039.png)
AU (1) AU6044894A (US06559137-20030506-C00039.png)
CA (1) CA2156287C (US06559137-20030506-C00039.png)
CZ (1) CZ290504B6 (US06559137-20030506-C00039.png)
DE (1) DE69430664T2 (US06559137-20030506-C00039.png)
ES (1) ES2176236T3 (US06559137-20030506-C00039.png)
FI (1) FI112652B (US06559137-20030506-C00039.png)
HU (1) HUT74105A (US06559137-20030506-C00039.png)
MY (1) MY128102A (US06559137-20030506-C00039.png)
NO (1) NO305201B1 (US06559137-20030506-C00039.png)
PL (1) PL176710B1 (US06559137-20030506-C00039.png)
RU (1) RU2128170C1 (US06559137-20030506-C00039.png)
TW (1) TW281669B (US06559137-20030506-C00039.png)
WO (1) WO1994019322A1 (US06559137-20030506-C00039.png)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
KR100235161B1 (ko) * 1993-11-26 2001-11-22 찌바따 이찌로, 다나까 도시오 2-옥소인돌린 유도체
DE69512220T2 (de) * 1994-03-07 2000-03-16 Vertex Pharma Sulfonamidderivate als aspartylprotease-inhibitoren
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU2233097A (en) * 1996-03-11 1997-10-01 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of optically active indole compounds
WO1998002419A1 (fr) * 1996-07-12 1998-01-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation de cellules cancereuses
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9912169A (pt) 1998-06-19 2001-04-10 Vertex Pharma Inibidores de sulfonamida de protease de aspartil
ATE285769T1 (de) * 1998-12-04 2005-01-15 Neurosearch As Verwendung von isatinderivaten als ionenkanalaktivierende mittel
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP4058243B2 (ja) * 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US20030187054A1 (en) * 2000-03-10 2003-10-02 Shunsuke Nagao Preparations for chondrogenesis
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
WO2001098269A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
CN1324009C (zh) * 2003-01-30 2007-07-04 普文英 化合物1－n－甲氧基－2－氧－吲哚－3－乙酰胺及其药物用途
WO2008027692A2 (en) * 2006-08-02 2008-03-06 Abu-Ageel Nayef M Led-based illumination system
US20090050905A1 (en) * 2007-08-20 2009-02-26 Abu-Ageel Nayef M Highly Efficient Light-Emitting Diode
US20100202129A1 (en) * 2009-01-21 2010-08-12 Abu-Ageel Nayef M Illumination system utilizing wavelength conversion materials and light recycling
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN102516153B (zh) * 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
PL3071206T3 (pl) 2013-11-22 2022-01-17 CL BioSciences LLC Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
KR102161674B1 (ko) * 2014-02-18 2020-10-05 주식회사 대웅제약 이사틴 유도체 및 이의 제조방법
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
JPS62228072A (ja) * 1985-12-20 1987-10-06 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
JPS62234080A (ja) * 1985-12-20 1987-10-14 Kissei Pharmaceut Co Ltd インドリン−２−オン誘導体
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
JPS62270576A (ja) * 1986-05-19 1987-11-24 Kissei Pharmaceut Co Ltd イサチン誘導体
JPS63156771A (ja) * 1986-12-19 1988-06-29 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
JPS62156771A (ja) * 1986-12-19 1987-07-11 Tokyo Shokai:Kk 処方箋処理装置
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
JP3356431B2 (ja) * 1990-08-31 2002-12-16 ワーナー―ランバート・コンパニー Ｃｃｋアンタゴニストに対するプロ―ドラッグ
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
CA2055094A1 (en) * 1990-11-13 1992-05-14 Mark G. Bock Cholecystokinin antagonist
JPH05104510A (ja) * 1991-10-18 1993-04-27 Inax Corp 基板へのモルタル塗布方法

Also Published As

Publication number Publication date
PL176710B1 (pl) 1999-07-30
NO305201B1 (no) 1999-04-19
HU9502415D0 (en) 1996-05-28
US6114536A (en) 2000-09-05
MY128102A (en) 2007-01-31
CN1117727A (zh) 1996-02-28
JPH0748349A (ja) 1995-02-21
US6127544A (en) 2000-10-03
WO1994019322A1 (en) 1994-09-01
CZ290504B6 (cs) 2002-08-14
US6031111A (en) 2000-02-29
US6207836B1 (en) 2001-03-27
NO953235D0 (no) 1995-08-17
US5952511A (en) 1999-09-14
CN1046268C (zh) 1999-11-10
ES2176236T3 (es) 2002-12-01
ATE217864T1 (de) 2002-06-15
DE69430664D1 (de) 2002-06-27
CA2156287A1 (en) 1994-09-01
KR960701011A (ko) 1996-02-24
FI953866A (fi) 1995-08-16
PL310168A1 (en) 1995-11-27
CA2156287C (en) 2005-12-27
FI112652B (fi) 2003-12-31
EP0685463B1 (en) 2002-05-22
JP3419539B2 (ja) 2003-06-23
KR100226310B1 (ko) 1999-10-15
RU2128170C1 (ru) 1999-03-27
EP0685463A4 (US06559137-20030506-C00039.png) 1996-01-03
TW281669B (US06559137-20030506-C00039.png) 1996-07-21
EP0685463A1 (en) 1995-12-06
FI953866A0 (fi) 1995-08-16
CZ209695A3 (en) 1995-12-13
AU6044894A (en) 1994-09-14
HUT74105A (en) 1996-11-28
NO953235L (no) 1995-10-09

Similar Documents

Publication Publication Date Title
DE69430664T2 (de) Indolin-2-on-derivate
PE20051056A1 (es) Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, aracnidos y nematodos
CY1113118T1 (el) Παραγωγα πυριμιδινης
ATE248823T1 (de) 1,5-benzodiazepinderivate
RS39604A (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
TR199902724T2 (xx) Dopamine D3 resept�rleri mod�lat�rleri olarak tetrahidroisokuinolin t�revleri.
ATE171162T1 (de) 5-(2-oxyphenyl)-pyrrol-derivate als dopamin-d3- rezeptor-antagonisten
DE69319925T2 (de) Indol-piperazin-derivate als selektive liganden der 5ht1d und 5ht1b receptoren verwendbar als arzneimittel
HUP0203839A2 (hu) 4-Fenil-1-piperazinil-, -piperidinil- és tetrahidropiridil-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO995289D0 (no) Benzimidazol-derivater
DE69430068T2 (de) Benzodiazepinderivate
BR9506763A (pt) Derivados de carbamoil metil uréia
FI860443A (fi) 5-sulfonamido-1-aryl-pyrazoler.
TH17368EX (th) อนุพันธ์ของอินโดลิน-2-โอน
TH17368A (th) อนุพันธ์ของอินโดลิน-2-โอน

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee